Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Study ID
NCT05503667
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • EGFR Gene Mutation
  • Lung Adenocarcinoma Stage III
  • Lung Adenocarcinoma Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Furmonertinib — DRUG
    Furmonertinib 80 mg/day for 16 weeks
  • Bevacizumab — DRUG
    bevacizumab 400 mg/4 weeks i.v. for 4 times

Study Details

To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.

Key Dates

Start date
Feb 1, 2022
Status verified
Aug 2022
Primary completion
Oct 1, 2023
Completion
Dec 31, 2028

Study Design

Enrollment
96 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Furmonertinib Plus Bevacizumab
    Furmonertinib Plus Bevacizumab
  • Active Comparator: Furmonertinib
    Furmonertinib monotherapy

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: up to 21 months ]

Central Contacts

Related Studies